Follistatin 344

Follistatin 344 (FS344) is a follistatin protein that blocks two molecules — myostatin and activin — that act as the body’s natural “brakes” on muscle growth. It’s a real, active substance. But it’s clinically unproven: the only proper human testing was small, early-stage gene therapy for muscular dystrophy, even those headline results were challenged by other doctors, and there is no human evidence for the muscle-building or fat-loss uses it’s actually sold for. This page is meant to inform and reduce harm. It contains no doses, cycles, or sourcing.

What it is

Follistatin is a protein your body makes and releases on its own. Its job is to grab onto and shut down a few signaling molecules in the TGF-β family (a group of related proteins that control cell growth) — most importantly myostatin (GDF-8) and activin A (and to a lesser degree GDF-11). Once follistatin latches onto these molecules, they can no longer dock with their landing pads on muscle cells — the activin type II receptors (ActRIIA/ActRIIB). That, in turn, switches off the downstream SMAD2/3 signaling (the internal chain of messages that normally holds muscle growth back). So the real effect is taking the foot off a “brake” on muscle building, rather than pressing a gas pedal to grow muscle directly.

The “344” points to one specific version of the protein — the 344-amino-acid splice variant (FS344), compared with the shorter FS288 and the longer FS315 versions. FS344 is a precursor form (an earlier version the body can later process). The three versions stick to cell surfaces with different strengths (FS288 clings the most tightly), and that difference is part of why FS344 was picked for whole-body gene-therapy work.

One important caveat: follistatin blocks activin and related molecules broadly — not just myostatin. That makes it a fairly non-specific blocker, hitting more than one target. That detail matters for judging both how well it works and how safe it is.

It’s also worth being clear about how it was given. The legitimate human research used follistatin as an AAV gene therapy — meaning DNA carrying the FS344 gene was injected into muscle, so the body itself would make the protein — not as a ready-made injectable peptide. The “Follistatin 344 peptide” sold by research-chemical and gray-market vendors is research-grade material with no clinical development behind it as an injectable protein, and it is not the same thing as the trial gene therapy.

The claims

Gray-market sellers pitch injectable “Follistatin 344” for muscle growth, fat loss, faster recovery, and even hair regrowth. The jaw-dropping pictures they lean on — huge gains in lean mass, “double-muscled” physiques — come from animal and preclinical experiments (early lab work, not human trials) that tinkered with myostatin and follistatin in rodents and monkeys, not from people. None of these vendor claims are backed by controlled human data.

What the evidence actually shows

Two small open-label gene-therapy trials (studies where everyone knew they were getting the treatment, with no comparison group) are the only meaningful human data we have. Both used the construct rAAV1.CMV.huFollistatin344 (written as AAV1.CMV.FS344 in the muscular-dystrophy/myositis paper — it’s the same thing).

Becker muscular dystrophy + sporadic inclusion body myositis (NCT01519349, Phase 1). The Becker group — 6 male patients who could still walk — was reported in Mendell JR et al., Molecular Therapy 2015;23(1):192–201 (PMID 25322757). Results on the six-minute-walk test (how far someone can walk in six minutes) were all over the map: roughly +58 m and +125 m at the lower dose with one patient unchanged, and +108 m and +29 m at the higher dose with one patient not improving. Muscle samples taken after treatment showed less scarring (fibrosis) and bigger muscle fibers, especially at the higher dose, and the authors reported no adverse effects.

Here’s the single most important honesty point: these are not controlled-trial results. A published critique — Greenberg SA, Molecular Therapy 2017 (PMID 28927986) — argued that the study can’t actually prove the treatment works, especially for the inclusion-body-myositis patients. The reasons: there was no comparison group, the patients were also on prednisone (a steroid) and exercising at the same time, the team reported a different, after-the-fact “annualized” walk-test result instead of the safety goal they had originally registered, and a side-effect count (falls) was misstated.

Duchenne muscular dystrophy (NCT02354781, Phase 1/2). This trial enrolled 3 patients, and its main goal was safety (watching for dose-limiting toxicity — serious side effects bad enough to cap the dose — over 2 years). One serious event was a fall that caused a head injury. No peer-reviewed report on whether it actually worked could be found, so treat it as inconclusive.

Weight loss and metabolic use: no human evidence at all. There are no completed human trials of follistatin (any version) for obesity, fat loss, or metabolic disease. Any claims about changing body composition come from animal studies — that’s a guess extended to humans, not a human finding.

So the overall picture is a genuine biological mechanism paired with a tiny, disputed early-stage human hint in muscle disease — and nothing at all supporting the fitness uses it’s sold for.

Legal and regulatory status

Follistatin is not approved by any regulator (FDA or EMA) for any use — not for muscle, not for weight loss, not for metabolic disease. There is no approved follistatin drug, period. The legitimate human work was an experimental gene-transfer biologic that only made it to early-stage testing.

In sport, follistatin is banned by WADA (the World Anti-Doping Agency) at all times under the 2026 Prohibited List, category S4 (Hormone and Metabolic Modulators), subsection S4.3 — “Agents preventing activin receptor IIB activation.” That subsection covers myostatin-binding proteins (such as follistatin and myostatin propeptide), decoy/soluble activin receptors and anti-ActRIIB antibodies (such as ACE-031 and bimagrumab), and myostatin-neutralizing antibodies (such as apitegromab and domagrozumab). So follistatin sits in the same activin-receptor-IIB family as ACE-031. (The subsection number has moved around between editions — it was S4.4 in some earlier lists — but the heading wording and follistatin’s place in it have stayed the same.) For comparison, IGF-1 and mechano growth factors fall under a different category, S2 (peptide hormones, growth factors, and mimetics).

Safety

Human safety data are extremely thin — they come from only about a dozen patients in total, spread across two tiny, uncontrolled gene-therapy studies. The “no adverse effects” reported in the Becker paper reflects a handful of people watched for a limited time, not a safety profile you can generalize to anyone else.

The mechanism raises questions we can’t yet answer in humans. Because follistatin and activin signaling touch many systems (they’re “pleiotropic” — meaning one pathway affects several different body functions), blocking them broadly raises reasonable worries about effects on reproduction and hormones (activin is involved in both), and the myostatin/activin–ActRIIB system also plays a role in the heart and blood vessels. The clearest real-world warning sign for this broader pathway comes from a related drug, not follistatin itself: the ACE-031 program (a decoy ActRIIB receptor designed to soak up these signals) was stopped by its data safety monitoring board and discontinued (Acceleron, around 2013) after side effects outside the muscle — notably epistaxis (nosebleeds) and telangiectasias (small abnormal blood vessels visible in the skin) — that were blamed on the drug accidentally interfering with BMP9/BMP10 signaling that keeps blood vessels healthy. This is well-established background for the whole activin-receptor pathway, not something seen with follistatin specifically — but it shows why blocking this pathway broadly deserves caution.

Gray-market injectable “Follistatin 344” peptide carries the usual research-chemical risks — no GMP manufacturing (no certified pharmaceutical-quality production), unknown purity and identity, plus the risk of endotoxin (bacterial contamination that can cause fever and worse) and non-sterile product — stacked on top of a mechanism that isn’t proven to begin with. There is no established safe way to use it, and no dosing guidance exists or should be inferred. None of this is medical advice.

Bottom line

Follistatin 344 is a myostatin/activin-pathway blocker that is scientifically real and biologically active, but clinically unproven. Its only legitimate human testing was small early-stage AAV gene therapy in muscular dystrophy, the headline functional claims — especially in inclusion body myositis — were credibly disputed in the peer-reviewed literature, and there is no human evidence for weight loss or metabolic use. It isn’t approved for anything, and it’s WADA-prohibited at all times under S4.3. The marketing runs far ahead of the evidence.

Evidence grade: 6/10 · Preliminary.

Sources

• Mendell JR et al., A Follistatin Gene Therapy Trial for Becker Muscular Dystrophy, Molecular Therapy 2015 (PMID 25322757)
• Mendell et al. full text (PMC4426808)
• Greenberg SA, Unfounded Claims of Improved Functional Outcomes Attributed to Follistatin Gene Therapy in Inclusion Body Myositis, Molecular Therapy 2017 (PMID 28927986)
• ClinicalTrials.gov NCT01519349 — rAAV1.CMV.huFollistatin344 in Becker MD and sporadic inclusion body myositis
• ClinicalTrials.gov NCT02354781 — rAAV1.CMV.huFollistatin344 in Duchenne MD
• WADA 2026 Prohibited List
• WADA 2026 Prohibited List (official PDF mirror, S4.3)